Skip to main content
. Author manuscript; available in PMC: 2015 Oct 30.
Published in final edited form as: Nature. 2015 Apr 22;520(7549):697–701. doi: 10.1038/nature14418

Extended Data Figure 8. Suppression of POLR2A with DOPC-encapsulated POLR2A siRNA inhibits the growth of POLR2Aloss tumours.

Extended Data Figure 8

a, Protein levels of POLR2A following transfection of control siRNA or POLR2A siRNAs (#1 and #2) in HCT116 cells. b, Schematic illustration of orthotopic injection of HCT116 cells (1 × 106 cells) followed by siRNA-DOPC nanoliposome treatment. c–f, Representative bioluminescent images (c, e) and tumour growth curves (d, f) of orthotopic xenograft tumours derived from POLR2Aneutral and POLR2Aloss HCT116 cells that received intraperitoneal injections of control (1,000μg kg−1) or POLR2A siRNAs (125, 250, 500 and 1,000 μg kg−1) twice weekly. n = 10 mice per group. Error bars, s.e.m. (g, h) Representative protein levels of POLR2A in xenograft tumours following control or POLR2A siRNA treatment.